PT  - JOURNAL ARTICLE
AU  - MASAYUKI FUJIWARA
AU  - HIROSHI DOI
AU  - MASATAKA IGETA
AU  - HITOMI SUZUKI
AU  - KAZUHIRO KITAJIMA
AU  - MASAO TANOOKA
AU  - TOSHIHISA ISHIDA
AU  - TSUKASA WAKAYAMA
AU  - TAKASHI YOKOI
AU  - KOZO KURIBAYASHI
AU  - TAKASHI KIJIMA
AU  - MASAKI HASHIMOTO
AU  - NOBUYUKI KONDO
AU  - SEIJI MATSUMOTO
AU  - SEIKI HASEGAWA
AU  - NORIHIKO KAMIKONYA
AU  - KOICHIRO YAMAKADO
TI  - Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer
AID  - 10.21873/anticanres.15396
DP  - 2021 Nov 01
TA  - Anticancer Research
PG  - 5793--5802
VI  - 41
IP  - 11
4099  - http://ar.iiarjournals.org/content/41/11/5793.short
4100  - http://ar.iiarjournals.org/content/41/11/5793.full
SO  - Anticancer Res2021 Nov 01; 41
AB  - Background/Aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC). Patients and Methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors. The prescribed radiation dose for the gross tumor and the elective nodal area was 69 Gy in 30 fractions and 51 Gy in 30 fractions, respectively. Results: Radiation pneumonitis developed in 38 patients (76%, 38/50), and grade ≥2 radiation pneumonitis developed in 11 patients (22%, 11/50). The percentage of lung volume that received a dose in excess of 5 Gy (V5), V10, V20, V30, and the mean lung dose (MLD) in the bilateral and ipsilateral lung were significantly associated with the development of grade ≥2 radiation pneumonitis. Conclusion: The incidence and degree of radiation pneumonitis are acceptable following treatment of NSCLC with VMAT.